Dutch to reimburse Exogen's ultrasound:
This article was originally published in Clinica
Executive Summary
The Dutch government has approved the reimbursement of Exogen's ultrasound therapy from April 1, for use on non-healing bone fractures of longer than six months. This is the first ultrasound therapy to win reimbursement approval in Europe. Piscataway, New Jersey-based Exogen's low-intensity, non-invasive treatment is already reimbursed in the US, where it is marketed by Smith & Nephew, and in Japan, where it was launched by Teijin.